Lung Cancer in 2007: A Multidisciplinary Approach

Minnesota Oncology Hematology
Ultima Vez Modificado: 14 de septiembre del 2007

Share article


Conference Dates: October 6, 2007
Conference Location: Minneapolis, Minnesota

Sponsoring Group: Minnesota Oncology Hematology, PA

Conference Web Page URL: http://www.lungcancer2007.com

Topics Covered: The CME/CE accredited program, Lung Cancer Care in 2007: A Multidisciplinary Approach, offers a unique opportunity for community-based oncologists and other cancer care providers to rapidly acquire knowledge of the most recent advances in non-small cell lung cancer treatment. A diverse group of community and academic lung cancer experts will discuss the immediate integration of novel treatments into the community setting. Participants will take away practical information to assist in delivering the most effective cancer-fighting strategies for their patients.

Conference Objectives: At the conclusion of the program, participants will be able to:

Who Should Attend: This continuing medical education program is intended for community-based medical, surgical, and radiation oncologists; thoracic surgeons; pulmonologists; and fellows. Primary care physicians, nurses, pharmacists, and midlevel practitioners involved in the care of lung cancer patients are also encouraged to attend.

Conference Agenda: Program Agenda (8:00AM – 3:00PM)

Treatment for Early Stage Lung Cancer

  • Overview of Chemotherapy in Adjuvant NSCLC
  • Update on the Current State of CT Screening
  • Role and Sequence of Combined Modality Treatment in NSCLC
  • Controversies in the Surgical Management of Early-Stage NSCLC
  • Early Stage Lung Cancer: Presentation of Challenging Cases and Panel Discussion
Treatment of Metastatic NSCLC
  • First-line Therapy: Beyond Cytotoxic Chemotherapy with the Introduction of Targeted Agents
  • Predictive Indicators for Response in NSCLC
  • Novel Strategies for Treating Second and Refractory Lung Cancer
  • Treatment of Metastatic NSCLC: Presentation of Challenging Cases and Panel Discussion

Conference Fees: FREE

Continuing Education: Yes

Miscellany: Program Faculty


News
Adjuvant Zoledronic Acid Not Beneficial in Breast Cancer

Sep 27, 2011 - For patients with early-stage breast cancer, the addition of zoledronic acid to standard adjuvant therapy does not offer any benefit for disease-free or overall survival, according to a study published in the New England Journal of Medicine to coincide with presentation at the 2011 European Multidisciplinary Cancer Congress, held from Sept. 23 to 27 in Stockholm, Sweden.



I Wish You Knew

How cancer patients have changed my life

View More



Blogs and Web Chats

OncoLink Blogs give our readers a chance to react to and comment on key cancer news topics and provides a forum for OncoLink Experts and readers to share opinions and learn from each other.




OncoLink OncoPilot

Frente a un nuevo diagnóstico de cáncer o de cambiar el curso de su tratamiento actual? Deje que nuestro personal de enfermería cáncer que ayudan a pasar!

Más información